Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Increases speed to market for drug developers working on nucleic acid therapeutics
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
